Economic Evaluation of Neutral-pH, Low-Glucose Degradation Product Peritoneal Dialysis Solutions Compared with Standard Solutions: A Secondary Analysis of the balANZ Trial

American Journal of Kidney Diseases

Volumn 65, Issue 5, 2015, Pages 773-779

  Howard, Kirsten ^a   Hayes, Alison ^a   Cho, Yeoungjee ^b,c   Cass, Alan ^d   Clarke, Margaret ^e   Johnson, David W ^b,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

^d MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^e Thomson Asia Pacific   (Singapore)

Author keywords

balANZ trial; Biocompatible; cost effectiveness; economic evaluation; end stage kidney disease (ESKD); hospitalisation; low glucose degradation product; neutral pH; peritoneal dialysis (PD); peritoneal dialysis solutions; peritonitis

Indexed keywords

DIALYSIS FLUID; GLUCOSE; BIOMATERIAL;

ADULT; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; FEMALE; HEALTH CARE COST; HEMODIALYSIS PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PERITONEAL DIALYSIS; PERITONITIS; PH; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY ANALYSIS; SENSITIVITY ANALYSIS; AGED; CHEMISTRY; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; BIOCOMPATIBLE MATERIALS; COST-BENEFIT ANALYSIS; DIALYSIS SOLUTIONS; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS;

EID: 84929029134     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2014.12.017     Document Type: Article

References (43)

1. A.K. Jain, P. Blake, P. Cordy, and A.X. Garg Global trends in rates of peritoneal dialysis J Am Soc Nephrol 23 3 2012 533 544
2. Fresenius Medical Care. ESRD patients in 2011 - a global perspective 2012. http://www.vision-fmc.com/files/download/ESRD/ESRD-Patients-in-2011.pdf. Accessed November 20, 2013.
3. S.J. Davies, W. Van Biesen, J. Nicholas, and N. Lameire Integrated care Perit Dial Int 21 suppl 3 2001 S269 S274
4. S.P. McDonald, M.R. Marshall, D.W. Johnson, and K.R. Polkinghorne Relationship between dialysis modality and mortality J Am Soc Nephrol 20 1 2009 155 163
5. P.G. Blake Integrated end-stage renal disease care: the role of peritoneal dialysis Nephrol Dial Transplant 16 suppl 5 2001 61 66
6. H. Lee, B. Manns, K. Taub, et al. Cost analysis of ongoing care of patients with end-stage renal disease: the impact of dialysis modality and dialysis access Am J Kidney Dis 40 3 2002 611 622
7. Brown F, Fulyani A, Dent H, Hurst K, McDonald S. Chapter 6: peritoneal dialysis. Australia & New Zealand Dialysis & Transplantation (ANZDATA) Registry 2011. http://www.anzdata.org.au/anzdata/AnzdataReport/34thReport/2011c06-peritoneal-v1.8.pdf. Accessed June 22, 2012.
8. D.W. Johnson, Y. Cho, B.E. Livingston, et al. Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes Kidney Int 77 10 2010 904 912
9. E.A. Brown, W. Van Biesen, F.O. Finkelstein et al. ISPD Working Party Length of time on peritoneal dialysis and encapsulating peritoneal sclerosis: position paper for ISPD Perit Dial Int 29 6 2009 595 600
10. Y. Kawaguchi, H. Kawanishi, S. Mujais, N. Topley, and D.G. Oreopoulos Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis Perit Dial Int 20 suppl 4 2000 S43 S55
11. J.D. Williams, K.J. Craig, and N. Topley et al. Morphologic changes in the peritoneal membrane of patients with renal disease J Am Soc Nephrol 13 2 2002 470 479
12. M.P. Catalan, B. Santamaria, A. Reyero, A. Ortiz, and J. Egido 3,4-Di-deoxyglucosone-3-ene promotes leukocyte apoptosis Kidney Int 68 3 2005 1303 1311
13. N. Topley In vitro biocompatibility of bicarbonate-based peritoneal dialysis solutions Perit Dial Int 17 1 1997 42 47
14. N. Topley, R. Mackenzie, M.M. Petersen, et al. In vitro testing of a potentially biocompatible continuous ambulatory peritoneal dialysis fluid Nephrol Dial Transplant 6 8 1991 574 581
15. J. Witowski, N. Topley, A. Jorres, T. Liberek, G.A. Coles, and J.D. Williams Effect of lactate-buffered peritoneal dialysis fluids on human peritoneal mesothelial cell interleukin-6 and prostaglandin synthesis Kidney Int 47 1 1995 282 293
16. J. Witowski, J. Wisniewska, K. Korybalska, et al. Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells J Am Soc Nephrol 12 11 2001 2434 2441
17. S. Mortier, A.S. De Vriese, R.M. McLoughlin, et al. Effects of conventional and new peritoneal dialysis fluids on leukocyte recruitment in the rat peritoneal membrane J Am Soc Nephrol 14 5 2003 1296 1306
18. H.T. Schambye Effect of different buffers on the biocompatibility of CAPD solutions Perit Dial Int 16 suppl 1 1996 S130 S136
19. E. Boulanger, M.P. Wautier, J.L. Wautier, et al. AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression Kidney Int 61 1 2002 148 156
20. O. Devuyst, N. Topley, and J.D. Williams Morphological and functional changes in the dialysed peritoneal cavity: impact of more biocompatible solutions Nephrol Dial Transplant 17 suppl 3 2002 12 15
21. R. Mackenzie, C.J. Holmes, S. Jones, J.D. Williams, and N. Topley Clinical indices of in vivo biocompatibility: the role of ex vivo cell function studies and effluent markers in peritoneal dialysis patients Kidney Int Suppl 88 2003 S84 S93
22. V. Stankovic-Popovic, V. Nesic, D. Popovic, et al. Effects of conventional versus biocompatible peritoneal dialysis solutions on peritoneal and systemic inflammation, malnutrition and atherosclerosis in CAPD patients Clin Nephrol 76 4 2011 314 322
23. J. Furkert, M. Zeier, and V. Schwenger Effects of peritoneal dialysis solutions low in GDPs on peritonitis and exit-site infection rates Perit Dial Int 28 6 2008 637 640
24. S.H. Han, S.V. Ahn, J.Y. Yun, A. Tranaeus, and D.S. Han Mortality and technique failure in peritoneal dialysis patients using advanced peritoneal dialysis solutions Am J Kidney Dis 54 4 2009 711 720
25. H.Y. Lee, H.Y. Choi, and H.C. Park et al. Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome Nephrol Dial Transplant 21 10 2006 2893 2899
26. H.Y. Lee, B.J. Seo, J.Y. Do, et al. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance) Perit Dial Int 25 3 2005 248 255
27. D.W. Johnson, F.G. Brown, M. Clarke, et al. Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes J Am Soc Nephrol 23 6 2012 1097 1107
28. Brown F, Gulyani A, McDonald S, Hurst K. Chapter 6: peritoneal dialysis. In: ANZDATA 2012 Annual Report - 35th edition 2012. http://www.anzdata.org.au/anzdata/AnzdataReport/35thReport/2012c06-peritoneal-v3.pdf. Accessed November 21, 2013.
29. N. Boudville, A. Kemp, P. Clayton, et al. Recent peritonitis associates with mortality among patients treated with peritoneal dialysis J Am Soc Nephrol 23 8 2012 1398 1405
30. L. Troidle, and F. Finkelstein Treatment and outcome of CPD-associated peritonitis Ann Clin Microbiol Antimicrob 5 2006 6
31. P.K. Li, C.C. Szeto, B. Piraino, et al. Peritoneal dialysis-related infections recommendations: 2010 update Perit Dial Int 30 4 2010 393 423
32. D.W. Johnson, F.G. Brown, M. Clarke, et al. The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment, and outcomes: the balANZ trial Perit Dial Int 32 5 2012 497 506
33. B. Piraino, J. Bernardini, E. Brown, et al. ISPD position statement on reducing the risks of peritoneal dialysis-related infections Perit Dial Int 31 6 2011 614 630
34. Australian Department of Health. Round 14 (2009-10) National Public Cost Weight Tables - version 6.0x and version 5.2. 2012. http://www.health.gov.au/internet/main/publishing.nsf/Content/Round-14-cost-reports. Accessed April 28, 2013.
35. Australian Department of Health. Medicare Benefits Schedule. www.mbsonline.gov.au. Accessed January 25, 2015.
36. Australian Department of Health. Australian Pharmaceutical Benefits Scheme. www.pbs.gov.au. Accessed January 25, 2015.
37. PBAC Committee. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (version 4.3). Department of Health and Ageing, Australian Government, 2008. http://www.pbac.pbs.gov.au/content/information/archived-versions/pbac-guidelines-v4.3-2008.pdf. Accessed November 21, 2013.
38. E. Fenwick, D. Marshall, A. Levy, and G. Nichol Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation BMC Health Serv Res 6 2006 52
39. P.J. Neumann, J.T. Cohen, and M.C. Weinstein Updating cost-effectiveness - the curious resilience of the $50,000-per-QALY threshold N Engl J Med 371 9 2014 796 797
40. Dakin H, Devlin N, Feng Y, Rice N, O'Neill P, Parkin D. The influence of cost-effectiveness and other factors on NICE decisions. 2014. http://www.herc.ox.ac.uk/downloads/NICE. Accessed October 14, 2014.
41. The National Institute for Health and Clinical Excellence. Guide to methods of technology appraisal 2013. http://www.nice.org.uk/article/pmg9/resources/non-guidance-guide-to-the-methods-of-technology-appraisal-2013-pdf. Accessed October 14, 2014.
42. A.H. Harris, S.R. Hill, G. Chin, J.J. Li, and E. Walkom The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994-2004 Med Decis Making 28 5 2008 713 722
43. Y. Cho, D.W. Johnson, S.V. Badve, J.C. Craig, G.F. Strippoli, and K. Wiggins Impact of neutral pH, low glucose degradation product peritoneal dialysis solution on clinical outcomes in peritoneal dialysis: a systematic review of randomized controlled trials Kidney Int 84 5 2013 969 979